Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162678 · ClinicalTrials.gov registry record
Fluid Biopsy for the Diagnosis of Lung Cancer
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 51
- Enrollment target
NCT04162678: Clinical Trial study, sponsored by University of Southern California.
NCT04162678 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04162678 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
Primary Outcome
Descriptive statistics including sensitivity, specificity, positive, and negative predictive value will be tabulated.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Medical Chart Review
- PROCEDURE Liquid Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2024-12-09 |
Why NCT04162678 stopped before completion
NCT04162678 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04162678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04162678 about?
NCT04162678 is a clinical study titled "Fluid Biopsy for the Diagnosis of Lung Cancer". This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
What is the current status of trial NCT04162678?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2020-01-13. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT04162678?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Medical Chart Review (OTHER), Liquid Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04162678?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI